首页> 外文期刊>Circulation. Genomic and precision medicine. >Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/ Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition A Genome-Wide Association Study and Mendelian Randomization Study in the HUNT, Norway
【24h】

Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/ Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition A Genome-Wide Association Study and Mendelian Randomization Study in the HUNT, Norway

机译:血清PCSK9的变化(Proprotein转化酶枯草杆菌蛋白酶/可馨类型9),心血管疾病潜在的风险,一个调查意外PCSK9抑制的影响全基因组关联研究和孟德尔随机化研究打猎,挪威

获取原文
获取原文并翻译 | 示例
           

摘要

PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors reduce serum LDL (low-density lipoprotein) cholesterol (LDL-C) by increasing uptake in the liver.1 Although some long-term trials have evaluated their safety, broad investigations of outcomes over the lifetime, leveraging genetic variation in serum PCSK9, have seldomly been conducted. We investigated effects of these variants on a range of outcomes to explore unanticipated effects of long-term PCSK9 inhibition.
机译:PCSK9 (proprotein转化酶枯草杆菌蛋白酶/可馨类型9)抑制剂降低血清LDL(低密度脂蛋白胆固醇(低密度脂蛋白)增加吸收的liver.1试验评估其安全性,广泛在一生中,调查的结果利用血清PCSK9基因变异,就更难了。这些变异在一系列的结果探讨长期PCSK9的意想不到的影响的抑制。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号